Search Results for: 19

ROCKVILLE, Md., April 23, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned […]

ROCKVILLE, Md., March 7, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has received written communication from NYSE American LLC (the “Exchange”), the Company’s current listing exchange, stating that it is not in

— Company Provides Update on Late-stage Microbiome-focused Product Candidates — — Conference Call Today, February 22, 2018, at 8:30 a.m. (EST) — ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a

— Conference Call Scheduled for Thursday, February 22, 2018 at 8:30 a.m. EST — ROCKVILLE, Md., Feb. 15, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for

ROCKVILLE, Md., Jan. 2, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steven Shallcross, Interim CEO & CFO, is scheduled to present at the Biotech Showcase™ 2018 Conference next week in San Francisco, as

ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company’s Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an

— Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Held Initial Type-B Multidisciplinary Meeting with FDA to Discuss Late-Stage Clinical Advancement for SYN-004 (ribaxamase) — — Conference Call Today, November 1, 2017, at 4:30 p.m. EDT — ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners,

— SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI — — Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 — — Conference Call Today, August 3, 2017, at 8:30 a.m. EDT — ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage

— Conference Call Scheduled for Thursday, August 3, 2017 at 8:30 a.m. EDT — ROCKVILLE, Md., July 27, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights